Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RedHill Biopharma ( (RDHL) ) has provided an update.
RedHill Biopharma Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for May 5, 2025, in Tel Aviv, Israel. Key agenda items include the appointment of Kesselman & Kesselman as auditors, the re-election of board members, approval of a renewed compensation policy, and the granting of restricted share units to key executives and directors. These proposals are aimed at strengthening the company’s governance and aligning executive incentives with shareholder interests.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a biopharmaceutical company based in Tel Aviv, Israel. The company focuses on the development and commercialization of late clinical-stage, proprietary, and orally-administered drugs for the treatment of gastrointestinal and infectious diseases.
YTD Price Performance: -58.44%
Average Trading Volume: 90,512
Technical Sentiment Signal: Buy
Current Market Cap: $3.39M
Learn more about RDHL stock on TipRanks’ Stock Analysis page.